Immune checkpoint inhibitors: The linchpins of modern immunotherapy

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in the past decade. While monoclonal antibodies to CTLA-4 and PD-1/PD-L1 have produced remarkable and durable responses in a subset of patients, the majority of patients will still develop primary or adaptive resistance. With complex mechanisms of resistance limiting the efficacy of checkpoint inhibitor monotherapy, it is critical to develop combination approaches to allow more patients to benefit from immunotherapy. In this review, I approach the current landscape of ICI research from the perspective of sarcomas, a rare group of bone and soft tissue cancers that have had limited benefit from checkpoint inhibitor monotherapy, and little investigation of biomarkers to predict responses. By surveying the various mechanisms of resistance and treatment modalities being explored in other solid tumors, I outline how ICIs will undoubtedly serve as the critical foundation for future directions in modern immunotherapy.

Original languageEnglish (US)
Pages (from-to)6-23
Number of pages18
JournalImmunological reviews
Volume290
Issue number1
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Immunotherapy
Neoplasms
Sarcoma
Biomarkers
Monoclonal Antibodies
Bone and Bones
Therapeutics
Research
Direction compound

Keywords

  • CTLA-4
  • immune checkpoint inhibitors
  • immunotherapy
  • PD-1
  • sarcomas
  • T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immune checkpoint inhibitors : The linchpins of modern immunotherapy. / Wilky, Breelyn A.

In: Immunological reviews, Vol. 290, No. 1, 01.07.2019, p. 6-23.

Research output: Contribution to journalReview article

@article{2f32b99a0e954da1be66fcc1657651cf,
title = "Immune checkpoint inhibitors: The linchpins of modern immunotherapy",
abstract = "Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in the past decade. While monoclonal antibodies to CTLA-4 and PD-1/PD-L1 have produced remarkable and durable responses in a subset of patients, the majority of patients will still develop primary or adaptive resistance. With complex mechanisms of resistance limiting the efficacy of checkpoint inhibitor monotherapy, it is critical to develop combination approaches to allow more patients to benefit from immunotherapy. In this review, I approach the current landscape of ICI research from the perspective of sarcomas, a rare group of bone and soft tissue cancers that have had limited benefit from checkpoint inhibitor monotherapy, and little investigation of biomarkers to predict responses. By surveying the various mechanisms of resistance and treatment modalities being explored in other solid tumors, I outline how ICIs will undoubtedly serve as the critical foundation for future directions in modern immunotherapy.",
keywords = "CTLA-4, immune checkpoint inhibitors, immunotherapy, PD-1, sarcomas, T cells",
author = "Wilky, {Breelyn A}",
year = "2019",
month = "7",
day = "1",
doi = "10.1111/imr.12766",
language = "English (US)",
volume = "290",
pages = "6--23",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Immune checkpoint inhibitors

T2 - The linchpins of modern immunotherapy

AU - Wilky, Breelyn A

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in the past decade. While monoclonal antibodies to CTLA-4 and PD-1/PD-L1 have produced remarkable and durable responses in a subset of patients, the majority of patients will still develop primary or adaptive resistance. With complex mechanisms of resistance limiting the efficacy of checkpoint inhibitor monotherapy, it is critical to develop combination approaches to allow more patients to benefit from immunotherapy. In this review, I approach the current landscape of ICI research from the perspective of sarcomas, a rare group of bone and soft tissue cancers that have had limited benefit from checkpoint inhibitor monotherapy, and little investigation of biomarkers to predict responses. By surveying the various mechanisms of resistance and treatment modalities being explored in other solid tumors, I outline how ICIs will undoubtedly serve as the critical foundation for future directions in modern immunotherapy.

AB - Immune checkpoint inhibitors (ICIs) have revolutionized our approach to cancer treatment in the past decade. While monoclonal antibodies to CTLA-4 and PD-1/PD-L1 have produced remarkable and durable responses in a subset of patients, the majority of patients will still develop primary or adaptive resistance. With complex mechanisms of resistance limiting the efficacy of checkpoint inhibitor monotherapy, it is critical to develop combination approaches to allow more patients to benefit from immunotherapy. In this review, I approach the current landscape of ICI research from the perspective of sarcomas, a rare group of bone and soft tissue cancers that have had limited benefit from checkpoint inhibitor monotherapy, and little investigation of biomarkers to predict responses. By surveying the various mechanisms of resistance and treatment modalities being explored in other solid tumors, I outline how ICIs will undoubtedly serve as the critical foundation for future directions in modern immunotherapy.

KW - CTLA-4

KW - immune checkpoint inhibitors

KW - immunotherapy

KW - PD-1

KW - sarcomas

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=85069960799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069960799&partnerID=8YFLogxK

U2 - 10.1111/imr.12766

DO - 10.1111/imr.12766

M3 - Review article

C2 - 31355494

AN - SCOPUS:85069960799

VL - 290

SP - 6

EP - 23

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -